Evidence map›Paper›PMID 30940485›Full record

Trial reportVaccine2019

Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men.

Ligia A Pinto, Timothy J Wilkin, Troy J Kemp, Martha Abrahamsen, Kimberly Isaacs-Soriano, Yuanji Pan, Jennifer Webster-Cyriaque, Joel M Palefsky, Anna R Giuliano

Open access · greenAbstract readClinical Trial, Phase IIComparative Study
In one paragraph

Trial report in Vaccine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Ligia A PintoHPV Immunology and HPV Serology Laboratories, Frederick National Laboratory for Cancer Research, Frederick, MD, United States. Electronic address: pintol@mail.nih.gov.
Timothy J WilkinWeill Cornell Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, NY, United States.
Troy J KempHPV Immunology and HPV Serology Laboratories, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
Martha AbrahamsenCenter for Immunization and Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.
Kimberly Isaacs-SorianoCenter for Immunization and Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.
Yuanji PanHPV Immunology and HPV Serology Laboratories, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
Jennifer Webster-CyriaqueUniversity of North Carolina, Chapel Hill, NC, United States.
Joel M PalefskyUniversity of California, San Francisco, CA, United States.
Anna R GiulianoCenter for Immunization and Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.
Frederick National Laboratory for Cancer Research · USMoffitt Cancer Center · USCornell University · USUniversity of California, San Francisco · USUniversity of North Carolina at Chapel Hill · US

Funding

Consortium for Advancing Management and Prevention of Cancer in People with HIVUM1CA121947 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Joseph A. Sparano · 2015 to 2026
$253.7M
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5M
AIDS and Cancer Specimen Resource (ACSR)UM1CA181255 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jeffrey Michael Bethony, Anna Coghill · 2013 to 2026
$56.7M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS Z99 CA999999NCI NIH HHS HHSN261200800001ENCI NIH HHS P30 CA076292NCI NIH HHS UM1 CA121947NCI NIH HHS UM1 CA181255
6 · The paper itself

Abstract

Duration and functional aspects of the oral and systemic antibody responses following HPV vaccination in HIV-negative (HIV

Indexed as

AlphapapillomavirusAntibodies, ViralHIV InfectionsHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18MouthPapillomavirus InfectionsAdultAntibodies, NeutralizingAntibody AffinityHuman papillomavirus 16Human papillomavirus 18HumansKineticsMaleMiddle AgedVaccinationAntibodies, NeutralizingAntibodies, ViralHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18HIVHPVHPV vaccineOral antibodies

Identifiers

PMID30940485
PMCPMC6863043
OpenAlexW2928100430

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.